10-Q: Ascend Wellness Holdings Reports Q2 2024 Results: Revenue Growth and Improved Margins

Ascend Wellness Holdings saw a 15% increase in revenue and improved gross margins in the second quarter of 2024, driven by wholesale expansion and acquisitions.

Summary

• Ascend Wellness Holdings reported a net revenue of $141.5 million for the second quarter of 2024, a 15% increase compared to the same period last year.
• The company's gross profit margin improved to 29.4% in Q2 2024, up from 23.0% in Q2 2023.
• Operating loss decreased significantly to $1.5 million, compared to $8 million in the prior year's second quarter.
• The company experienced a net loss of $21.8 million for the quarter, compared to a net income of $0.8 million in Q2 2023.
• For the first six months of 2024, net revenue reached $283.9 million, a 20% increase year-over-year.
• The company's gross profit margin for the first half of 2024 was 33.0%, compared to 27.0% in the first half of 2023.
• The net loss for the first six months of 2024 was $39.9 million, compared to a net loss of $17.6 million in the same period of 2023.
• The company had $83.7 million in cash and cash equivalents as of June 30, 2024.
• The company sold approximately 47,000 pounds of wholesale product in Q2 2024, compared to 33,000 pounds in Q2 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and improved gross margins, the company is still operating at a net loss and has significant debt. The future outlook is positive, but the company needs to execute well to achieve profitability.

Positives

• The company experienced significant revenue growth, particularly in wholesale operations.
• Gross profit margins improved substantially, indicating better cost management and pricing strategies.
• Operating losses decreased, suggesting improved operational efficiency.
• The company generated positive net cash from operating activities.
• The company expanded its cultivation capacity in Massachusetts.
• The company increased its retail footprint with new dispensaries.

Negatives

• The company reported a net loss of $21.8 million for the quarter, compared to a net income of $0.8 million in Q2 2023.
• The company experienced a net loss of $39.9 million for the first six months of 2024.
• General and administrative expenses increased by 19% in Q2 2024, driven by higher compensation and professional service fees.
• The company's legacy locations in Illinois and New Jersey saw a decrease in revenue due to increased competition.

Risks

• The company faces risks related to the illegality of cannabis under federal law.
• The company is subject to state and federal regulations, and compliance is crucial.
• The company faces uncertainty regarding the enforcement of cannabis laws.
• The company is subject to restricted access to banking and other financial services.
• The company faces unfavorable tax treatment for cannabis businesses.
• The company faces intense competition in the industry.
• The company faces risks related to material acquisitions, dispositions, and other strategic transactions.
• The company faces risks related to information technology systems.
• The company faces risks related to the results of future clinical research.
• The company faces risks related to the maturation of the cannabis market.
• The company faces risks related to adverse changes in wholesale and retail prices.
• The company faces risks related to sustained inflation.
• The company faces risks related to political and economic instability.
• The company faces risks related to outbreaks of pandemic diseases.
• The company faces risks related to general economic conditions.

Future Outlook

The company expects continued growth to be driven by opening new operational facilities and dispensaries under current licenses, expansion of current facilities, and increased consumer demand. The company anticipates completing the build-out of one additional dispensary in Pennsylvania and funding certain expansion projects across its retail operations. The company also anticipates completing certain projects across its cultivation facilities.

Management Comments

• Management believes that substantial doubt of our ability to continue as a going concern for at least one year from the issuance of our Financial Statements has been alleviated due to: (i) cash on hand and (ii) continued growth of sales from our consolidated operations.
• Management plans to continue to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs, as may be required.

Industry Context

The company's performance reflects the ongoing growth and competition within the cannabis industry, with expansion in new markets and increased wholesale activity driving revenue growth, while increased competition in mature markets impacts legacy locations. The company's focus on limited license markets and vertical integration is consistent with strategies employed by other successful multi-state operators.

Comparison to Industry Standards

• Compared to other multi-state operators (MSOs) like Curaleaf, Trulieve, and Green Thumb Industries, Ascend's revenue growth of 15% in Q2 2024 is within the range of growth seen by these companies, though some have reported higher growth rates.
• Ascend's gross margin of 29.4% in Q2 2024 is lower than some of the industry leaders, which often report gross margins above 40%, indicating room for improvement in cost management and pricing.
• The company's operating loss of $1.5 million in Q2 2024 is a significant improvement compared to the previous year, but some MSOs are already reporting operating profits, suggesting Ascend is still in a growth and investment phase.
• The company's adjusted EBITDA margin of 20.0% in Q2 2024 is comparable to some MSOs, but lower than others, indicating a need to improve profitability.
• The company's expansion into new markets and focus on vertical integration are consistent with industry best practices, but the company needs to continue to execute effectively to achieve industry-leading results.

Legal Proceedings

• The company is involved in ongoing litigation with MedMen NY, Inc. related to a terminated investment agreement.
• The company has established a reserve for potential losses related to the MedMen litigation.

Related Party Transactions

• The company has a secured promissory note with a retail dispensary license holder in Massachusetts, partially owned by an entity managed by one of the company's founders.

Stakeholder Impact

• Shareholders may be concerned about the net loss, but encouraged by the revenue growth and improved margins.
• Employees may benefit from the company's expansion and growth.
• Customers will have access to more dispensaries and products.
• Suppliers may see increased demand for their products.
• Creditors may be concerned about the company's debt levels, but reassured by the company's ability to generate cash.

Next Steps

• The company expects to complete the build-out of one additional dispensary in Pennsylvania.
• The company plans to fund certain expansion projects across its retail operations.
• The company anticipates completing certain projects across its cultivation facilities.
• The company plans to continue to access capital markets for additional funding.

Key Dates

Keywords

cannabis, multi-state operator, dispensaries, cultivation, wholesale, retail, revenue, gross profit, EBITDA, financial results, acquisitions, licenses